BCAX

Conviction 100HealthcareScan · Mon, Aug 10, 2026

BCAX$27.68-1.35%

ResistanceSupportVol 14Insider sell

Vol MA14 655.13K

May 11May 28Jun 16Jul 6Jul 23Aug 10

Bicara Therapeutics Inc.PHARMACEUTICAL PREPARATIONSwww.bicara.com ↗

Price27.68

Change-1.35%

Gap+1.03%

Rel volume3.12×

Avg volume580.65K

Avg $ vol15.77M

SMA 2027.23

SMA 5025.62

SMA 20020.19

Price vs 50+8.03%

Price vs 200+37.06%

MA stackbullish

50/200 cross—

Supertrendup · 25.70

RSI (14)55

MACD hist-0.07

MACD cross—

Stoch %K / %D65 / 67

ADX (14)19

+DI / −DI16 / 15

RSI divergence—

MACD divergence—

ATR %+5.12%

ADR %4.97%

52w high30.40

52w low9.99

From 52w high-8.95%

Above 52w low+177.08%

New 52w highNo

SqueezeOn · 2d

Bollinger width11.89%

%B0.64

Donchian pos65.36%

Donchian high28.92

Donchian low25.34

AVWAP (52w high)27.80

vs AVWAP high-0.42%

AVWAP (52w low)19.59

vs AVWAP low+41.31%

OBV trendFlat

Chaikin MF (20)-0.12

Today vs 20d3.12×

Avg vol (14d)655.13K

Avg vol (20d)580.65K

Avg $ vol (20d)15.77M

Market cap—

RS 3m (vs SPY)+15.83%

RS 6m (vs SPY)+71.71%

RS line new highNo

Trend template8/8

Technical rank79.7

1 week+7.54%

1 month-4.25%

3 months+22.59%

6 months+80.21%

1 year+171.37%

YTD+68.99%

P/E-13.36

P/B3.59

P/S—

P/FCF-17.21

EPS-2.52

Div yield—

ROE-26.84%

ROA-24.92%

Debt/Eq—

Current13.85

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth-102.88%

Price target32.11

Target upside14.43%

Analyst ratingBuy

Institutional110.05%

Ent. value1.52B

Revenue—

Net income-56.21M

Gross profit—

Free cash flow-107.11M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out65.7M

Employees103

ListedFri, Sep 13, 2024

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeA+

Conviction100 / 100

Pattern quality—

Tech rank79.7 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance30.45

Support23.06

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in BCAX

All disclosures →

No recent disclosed trades by Congress in BCAX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in BCAX · 2 buys · 8 sells

Insider	Side	Shares	Value	Traded	Filed
Cohlhepp Ryan President and COO · Common Stock · 2026-07-09	Sell	536	$16K	2026-07-09	2026-07-10
Hyep Ivan Chief Financial Officer · Common Stock · 2026-07-08	Sell	4.41K	$132K	2026-07-08	2026-07-10
Hyep Ivan Chief Financial Officer · Common Stock · 2026-07-08	Sell	830	$25K	2026-07-08	2026-07-10
Hyep Ivan Chief Financial Officer · Stock Option (Right to Buy) · 2026-07-08	Exercise	11.59K	—	2026-07-08	2026-07-10
Hyep Ivan Chief Financial Officer · Stock Option (Right to Buy) · 2026-07-08	Exercise	908	—	2026-07-08	2026-07-10
Hyep Ivan Chief Financial Officer · Common Stock · 2026-07-08	Exercise	12.5K	$47K	2026-07-08	2026-07-10
Cohlhepp Ryan President and COO · Common Stock · 2026-07-08	Exercise	18.75K	$71K	2026-07-08	2026-07-10
Cohlhepp Ryan President and COO · Common Stock · 2026-07-08	Sell	22.83K	$657K	2026-07-08	2026-07-10
Cohlhepp Ryan President and COO · Common Stock · 2026-07-08	Sell	4.31K	$128K	2026-07-08	2026-07-10
Cohlhepp Ryan President and COO · Common Stock · 2026-07-08	Sell	1.07K	$33K	2026-07-08	2026-07-10

SEC filings

EDGAR filings in BCAX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.